E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy

被引：43

作者：

Claudiani, Simone ^{[1
]}

Apperley, Jane F. ^{[1
]}

Gale, Robert Peter ^{[1
]}

Clark, Richard ^{[2
]}

Szydlo, Richard ^{[1
]}

Deplano, Simona ^{[1
]}

Palanicawandar, Renuka ^{[1
]}

Khorashad, Jamshid ^{[1
]}

Foroni, Letizia ^{[1
]}

Milojkovic, Dragana ^{[1
]}

机构：

[1] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Dept Haematol, London, England

[2] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England

来源：

HAEMATOLOGICA | 2017年 / 102卷 / 08期

关键词：

CHRONIC MYELOGENOUS LEUKEMIA; MOLECULAR RESPONSE; YOUNG-ADULTS; IMATINIB; E13A2; TRIAL;

D O I：

10.3324/haematol.2017.168740

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E297 / E299

页数：3

共 15 条

[1] Differences among young adults, adults and elderly chronic myeloid leukemia patients [J].

Castagnetti, F. ;

Gugliotta, G. ;

Baccarani, M. ;

Breccia, M. ;

Specchia, G. ;

Levato, L. ;

Abruzzese, E. ;

Rossi, G. ;

Iurlo, A. ;

Martino, B. ;

Pregno, P. ;

Stagno, F. ;

Cuneo, A. ;

Bonifacio, M. ;

Gobbi, M. ;

Russo, D. ;

Gozzini, A. ;

Tiribelli, M. ;

de Vivo, A. ;

Alimena, G. ;

Cavo, M. ;

Martinelli, G. ;

Pane, F. ;

Saglio, G. ;

Rosti, G. .

ANNALS OF ONCOLOGY, 2015, 26 (01) :185-192

[2] Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein [J].

Clark, RE ;

Dodi, IA ;

Hill, SC ;

Lill, JR ;

Aubert, G ;

Macintyre, AR ;

Rojas, J ;

Bourdon, A ;

Bonner, PLR ;

Wang, LH ;

Christmas, SE ;

Travers, PJ ;

Creaser, CS ;

Rees, RC ;

Madrigal, JA .

BLOOD, 2001, 98 (10) :2887-2893

[3] Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia [J].

Cross, N. C. P. ;

White, H. E. ;

Colomer, D. ;

Ehrencrona, H. ;

Foroni, L. ;

Gottardi, E. ;

Lange, T. ;

Lion, T. ;

Polakova, K. Machova ;

Dulucq, S. ;

Martinelli, G. ;

Leibundgut, E. Oppliger ;

Pallisgaard, N. ;

Barbany, G. ;

Sacha, T. ;

Talmaci, R. ;

Izzo, B. ;

Saglio, G. ;

Pane, F. ;

Mueller, M. C. ;

Hochhaus, A. .

LEUKEMIA, 2015, 29 (05) :999-1003

[4] Deep molecular responses for treatment-free remission in chronic myeloid leukemia [J].

Dulucq, Stephanie ;

Mahon, Francois-Xavier .

CANCER MEDICINE, 2016, 5 (09) :2398-2411

[5] Is there immune surveillance against chronic myeloid leukaemia? Possibly, but not much [J].

Gale, Robert Peter ;

Opelz, Gerhard .

LEUKEMIA RESEARCH, 2017, 57 :109-111

[6] Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib [J].

Hanfstein, Benjamin ;

Lauseker, Michael ;

Hehlmann, Ruediger ;

Saussele, Susanne ;

Erben, Philipp ;

Dietz, Christian ;

Fabarius, Alice ;

Proetel, Ulrike ;

Schnittger, Susanne ;

Haferlach, Claudia ;

Krause, Stefan W. ;

Schubert, Joerg ;

Einsele, Hermann ;

Haenel, Mathias ;

Dengler, Jolanta ;

Falge, Christiane ;

Kanz, Lothar ;

Neubauer, Andreas ;

Kneba, Michael ;

Stegelmann, Frank ;

Pfreundschuh, Michael ;

Waller, Cornelius F. ;

Spiekermann, Karsten ;

Baerlocher, Gabriela M. ;

Pfirrmann, Markus ;

Hasford, Joerg ;

Hofmann, Wolf-Karsten ;

Hochhaus, Andreas ;

Mueller, Martin C. .

HAEMATOLOGICA, 2014, 99 (09) :1441-1447

[7] Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors [J].

Jain, Preetesh ;

Kantarjian, Hagop ;

Patel, Keyur P. ;

Gonzalez, Graciela Nogueras ;

Luthra, Rajyalakshmi ;

Shamanna, Rashmi Kanagal ;

Sasaki, Koji ;

Jabbour, Elias ;

Romo, Carlos Guillermo ;

Kadia, Tapan M. ;

Pemmaraju, Naveen ;

Daver, Naval ;

Borthakur, Gautam ;

Estrov, Zeev ;

Ravandi, Farhad ;

O'Brien, Susan ;

Cortes, Jorge .

BLOOD, 2016, 127 (10) :1269-1275

[8] Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript [J].

Lucas, Claire M. ;

Harris, Robert J. ;

Giannoudis, Athina ;

Davies, Andrea ;

Knight, Katy ;

Watmough, Sarah J. ;

Wang, Lihui ;

Clark, Richard E. .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (10) :1362-1367

[9] Cessation of Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response: Results of the Euro-Ski Trial [J].

Mahon, Francois-xavier ;

Richter, Johan ;

Guilhot, Joelle ;

Hjorth-Hansen, Henrik ;

Almeida, Antonio ;

Janssen, Jeroen J. W. M. ;

Mayer, Jiri ;

Porkka, Kimmo ;

Panayiotidis, Panayiotis ;

Stromberg, Ulla ;

Berger, Marc G. ;

Diamond, Joanna ;

Ehrencrona, Hans ;

Kairisto, Veli ;

Polakova, Katerina Machova ;

Mueller, Martin C. ;

Mustjoki, Satu ;

Hochhaus, Andreas ;

Pfirrmann, Markus ;

Saussele, Susanne .

BLOOD, 2016, 128 (22)

[10] Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial [J].

Mahon, Francois-Xavier ;

Rea, Delphine ;

Guilhot, Joelle ;

Guilhot, Francois ;

Huguet, Francoise ;

Nicolini, Franck ;

Legros, Laurence ;

Charbonnier, Aude ;

Guerci, Agnes ;

Varet, Bruno ;

Etienne, Gabriel ;

Reiffers, Josy ;

Rousselot, Philippe .

LANCET ONCOLOGY, 2010, 11 (11) :1029-1035

← 1 2 →